20/20 Biolabs, Inc. AIDX
Nasdaq · XNAS · stock · Services-Testing Laboratories
Chart by TradingView
4/9
Piotroski F — financial health
-33.18
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.0M | -$3.7M | $604,541 | — | -$19,225 |
| 2024 | $1.8M | -$5.6M | $360,311 | — | $1.5M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -33.18 (distress)
- Working capital / assets -0.24
- Retained earnings / assets -8.036
- EBIT / assets -0.805
- Equity / liabilities -0.005
Source: SEC EDGAR filings · CIK 0001139685 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.